REVIEW
Authors Awosika O, Kim L, Mazhar M, Rengifo-Pardo M, Ehrlich A
Published 24 January 2018 Volume 2018:11 Pages 41—49
Olabola Awosika,1 Lori Kim,2 Momina Mazhar,2 Monica Rengifo-Pardo,1,2 Alison Ehrlich1,2
1Department of Dermatology, The George Washington Medical Faculty Associates, Washington, DC, USA; 2George Washington University School of Medicine & Health Sciences, Washington, DC, USA
Abstract: Atopic dermatitis (AD) is a common inflammatory skin disorder that manifests as eczematous lesions, often associated with allergic rhinitis and asthma.
Historically, moderate-to-severe disease has been managed with systemic immunosuppression, such as oral corticosteroids, which result in relapse and limiting side effects. Due to recent advancements in the identification of interleukin (IL)-4 and IL-13 as key mediators in AD, new biological agents have been developed for treatment. Dupilumab is a recently approved monoclonal antibody that targets the alpha subunit of the IL-4 receptor and, thus, downregulates activity of IL-4 and IL-13. This review discusses the profile of dupilumab and its potential for efficacy and safety in treating moderate-to-severe AD by reviewing data from Phase I–III clinical trials. Results suggest that dupilumab shows great therapeutic promise for AD. Further studies investigating extended use of dupilumab and dupilumab in comparison to other agents are needed to establish long-term efficacy and safety.1Department of Dermatology, The George Washington Medical Faculty Associates, Washington, DC, USA; 2George Washington University School of Medicine & Health Sciences, Washington, DC, USA
Abstract: Atopic dermatitis (AD) is a common inflammatory skin disorder that manifests as eczematous lesions, often associated with allergic rhinitis and asthma.
Keywords: atopic dermatitis, dupilumab, IL-4, IL-13, biologics
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
No comments:
Post a Comment